Cannabigerovarin (CBGV)
Molecular Formula: C19H28O2
Image credit: PubChem
CBGV is a potent inhibitor of LPI-induced GPR55 signaling.
Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, Ross RA.
J Biol Chem. 2012 Jan 2;287(1):91-104. doi: 10.1074/jbc.M111.296020. Epub 2011 Oct 25.
PMID: 22027819
CBGV has been shown to be holding great potential for treating cancer.
Study shows non-hallucinogenic cannabinoids are effective anti-cancer drugs.
St George's, University of London.
http://www.alphagalileo.org/ViewItem.aspx?ItemId=135404&CultureCode=en
CBGV was shown to be cytostatic in leukaemic cells and caused a simultaneous arrest at all phases of the cell cycle.
Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules.
Scott KA, Shah S, Dalgleish AG, Liu WM.
Anticancer Res. 2013 Oct;33(10):4373-80.
PMID: 24123005
CBGV is the propyl homologue of cannabigerol(CBG).
Cannabichromevarin and Cannabigerovarin, Two New Propyl Homologues of Cannabichromene and Cannabigerol
YUKIHIRO SHOYAMA, HITOTOSHI HIRANO, MIYUKI ODA, TAKAO SOMEHARA, ITSUO NISHIOKA
1) Faculty of Pharmaceutical Sciences, Kyushu University 2) Faculty of Pharmaceutical Sciences, Kyushu University 3) Faculty of Pharmaceutical Sciences, Kyushu University 4) Faculty of Pharmaceutical Sciences, Kyushu University 5) Faculty of Pharmaceutical Sciences, Kyushu University
http://doi.org/10.1248/cpb.23.1894
© 1999 - 2016 Copyright of